1. Introduction
===============

Allergic reactions induced by vaccine injections are a problematic event in small animal practice; these reactions are regarded as one of the adverse events occurring after vaccination ([@bib1], [@bib3]). The clinical signs of possible allergic reactions after vaccination in dogs are classified into two groups. The first group includes cardiovascular and/or respiratory signs such as circulatory collapse, cyanosis, hypotension, hypothermia, and dyspnea, which constitute anaphylaxis, whereas the second group includes dermatological signs such as facial edema, pruritus, and erythema ([@bib9]). In addition, some dogs were reported to die from the severe anaphylaxis after vaccination ([@bib7], [@bib9]). Allergic reactions after vaccination, therefore, have been considered as an important issue that needs to be resolved in veterinary practice.

Our previous study showed that IgE-mediated type I hypersensitivity was involved in the development of immediate-type allergic reactions after vaccination in dogs; this was indicated by the presence of high levels of IgE directed to the injected vaccines in the sera from dogs that developed allergic reactions after the vaccination ([@bib8]). Furthermore, it was observed that in most of the dogs that exhibited immediate-type allergic reactions, serum IgE was directed to fetal calf serum (FCS) ([@bib8]). It was also revealed that a large amount of bovine serum albumin (BSA) was included in the commercially available vaccines for dogs, which could be derived from FCS and/or BSA that are used for the growth of virus strains and leptospira included in vaccines ([@bib8]). These results indicated that FCS was a possible component to induce allergic reactions after vaccination in dogs.

FCS contains a variety of proteins; however, the types of components that induce IgE-mediated type I hypersensitivity after vaccination in dogs have not been clarified. Therefore, in the present study, by using an immunoblot analysis, we investigated the FCS components that reacted with IgE in the sera from dogs that developed allergic reactions after vaccination.

2. Materials and methods
========================

2.1. Dogs
---------

Serum samples from 16 dogs that had developed allergic reactions including cardiovascular and/or respiratory signs (circulatory collapse) as well as dermatological signs (facial edema, pruritus, and/or erythema) after non-rabies vaccination were collected by the cooperation of small animal practitioners in Japan. In these dogs, serum IgE directed to the injected vaccines was shown to be present by the procedure previously reported by us ([@bib8]). As negative controls, serum samples from 50 healthy dogs that had not developed any adverse reactions after vaccination were collected.

2.2. Vaccines
-------------

The commercially available non-rabies vaccines for dogs in Japan were classified into the following four groups: monovalent live canine parvovirus vaccine (group 1); monovalent inactivated canine parvovirus or leptospira vaccine (group 2); combined live vaccines composed of canine parvovirus, canine distemper virus, canine adenovirus type 2, and/or canine parainfluenza virus (group 3); combined live (canine parvovirus, canine distemper virus, canine adenovirus type 2, canine parainfluenza virus, and/or canine coronavirus) and inactivated (canine coronavirus and/or leptospira) vaccines (group 4).

2.3. Fluorometric indirect ELISA for detection of serum IgE directed to the injected vaccines and FCS
-----------------------------------------------------------------------------------------------------

Serum specific IgE directed to the injected vaccines and FCS was analyzed by a fluorometric ELISA system by using 1% cold water fish gelatin (Sigma--Aldrich) in PBS containing 0.05% Tween 20 as a blocking buffer and a mouse monoclonal anti-dog IgE antibody ([@bib2]) as a secondary antibody according to the procedure reported by us previously ([@bib11], [@bib12], [@bib8]). Serum IgE level was defined as positive when the fluorescence unit (FU) was higher than the threshold FU, which was obtained from the samples of healthy control dogs. The threshold FU was calculated from the mean value of FU plus three times of the standard deviation (S.D.) obtained from the IgE levels directed to the injected vaccines in 50 control dogs.

2.4. SDS-PAGE and immunoblot analysis
-------------------------------------

Heat-inactivated FCS (at 56 °C, for 30 min; JRH Biosciences, Lenexa, KS) and purified bovine proteins including BSA, bovine IgG, transferrin and fibronectin (all purchased from Sigma--Aldrich) were suspended in an SDS-PAGE sample buffer (Laemmli sample buffer, Bio-Rad Laboratories, Hercules, CA) containing β-mercaptoethanol, and boiled at 100 °C for 5 min. The samples (FCS: 2 μg/lane and BSA, bovine IgG, transferrin and fibronectin: 1 μg/lane) were subjected to SDS-PAGE through a 5--20% gradient polyacrylamide gel (ATTO, Tokyo, Japan). The protein concentration of FCS was measured by the Bradford method standardized with BSA. After the electrophoresis, the gel was stained with the Coomassie brilliant blue G-250 staining solution (Bio-Rad Laboratories). In the immunoblot analysis, the gel was electronically transferred onto a polyvinylidene difluoride (PDVF) membrane (Amersham Biosciences, Piscataway, NJ). The membrane was then blocked with 1% cold water fish gelatin (Sigma--Aldrich) in PBS containing 0.1% Tween 20 (PBST) at 4 °C overnight. After washing with PBST, the membrane was cut into strips, and then incubated with diluted serum samples (1:10) in 1% gelatin PBST at room temperature (RT) for 3 h. After washing with PBST, the strips were incubated with an HRP-conjugated goat anti-dog IgE antibody (1:25,000) (Bethyl Laboratories, Montgomery, TX) in 1% gelatin PBST at RT for 1 h. After washing, the IgE-binding proteins on a membrane were visualized using Lumi-Light^PLUS^ Western Blotting Substrate (Roche Applied Science, Indianapolis, IN) and captured using the ATTO Light Capture (ATTO).

3. Results and discussion
=========================

The clinical findings of the 16 dogs that developed allergic reactions after vaccination are shown in [Table 1](#tbl1){ref-type="table"} . Of these 16 dogs, two (Nos. 1 and 2) showed cardiovascular and/or respiratory signs such as circulatory collapse, and the remaining 14 dogs (Nos. 3--16) manifested dermatological signs such as facial edema, pruritus, and erythema. Within 60 min after vaccination, seven dogs (Nos. 1--7) developed clinical signs; these were clinically classified as immediate-type allergic reactions. The remaining nine dogs (Nos. 8--16) exhibited clinical signs between 2 and 20 h after vaccination; these were clinically classified as nonimmediate-type allergic reactions based on a previous report ([@bib9]). The FU values of serum IgE directed to the injected vaccines in these 16 dogs ranged between 156 and 2952 FU (mean ± S.D.: 993.6 ± 717.2 FU), and these values were higher than the threshold FU obtained from 50 control dogs (0--96 FU, mean ± S.D.: 16.6 ± 27.9 FU, threshold: 100.3 FU). Moreover, in all 16 dogs, high levels of serum IgE directed to FCS were observed (1100--5385 FU, mean ± S.D.: 2613.3 ± 1228.6 FU).Table 1Clinical findings and serum IgE reactivity to the injected vaccine and FCS in 16 dogs that developed allergic reactions after vaccinationDog numberBreedSexAgeNumber of previous vaccinationOnset time after vaccinationClinical signsGroup of the injected vaccine[a](#tbl1fn1){ref-type="table-fn"}Serum IgE reactivity (Fluorescence units)VaccineFCS1Shih tzuF2 months0≤5 minCirculatory collapse1 and 363920762Golden retrieverF5 years≥3≤5 minCirculatory collapse, vomiting, diarrhea438241743Miniature dachshundM3 monthsUnknown30--60 minFacial edema, pruritus4141513664PugF1 years 3 months≥320 minFacial edema449320145Shetland sheepdogMUnknown160 minFacial edema4151740666Shih tzuF2 years≥330 minFacial edema415625377Miniature dachshundF2 years 6 months≥330 minFacial edema, pruritus, vomiting441511008Miniature dachshundM5 years 5 months≥320 hFacial edema476636969MalteseM2 years 4 months≥37 hFacial edema, erythema, pruritus41041212210PugM3 years 5 months≥37 hFacial edema, pruritus, vomiting41429325011Shetland sheepdogM3 years 6 months22 hFacial edema42952538512Miniature dachshundF1 years 2 months≥32 hFacial edema4389124013Miniature dachshundM2 years 3 months≥35 hFacial edema31339341214Yorkshire terrierF5 months14--5 hFacial edema, pruritus4771262515Miniature dachshundF2 years≥32 h 30 minFacial edema4273144616BeagleF2 years 6 months≥310 hFacial edema, vomiting419201303[^1]

To investigate the allergenic component(s) of FCS, we carried out an immunoblot analysis using serum samples from the 16 dogs that had developed allergic reactions after vaccination. By SDS-PAGE, FCS was shown to contain several proteins including two major proteins that were observed at approximately 66- and 75-kDa ([Fig. 1](#fig1){ref-type="fig"}a). The 66-kDa protein was also identified as the most common IgE-binding protein in the immunoblot analysis of the serum of 14 of the 16 dogs (Dog Nos. 1--5 and 8--16) ([Fig. 1](#fig1){ref-type="fig"}b). In addition to the 66-kDa protein, several different types of FCS proteins, which strongly reacted with IgE in sera from the dogs, were detected at various molecular weights: 25-kDa (one dog: No.1), 50-kDa (one dog: No.1), 75-kDa (six dogs: Nos. 1, 6, 9, 10, 11, and 15), 120-kDa (three dogs: Nos. 6, 11, and 15) and 175-kDa (seven dogs: Nos. 6, 7, 11, 13, 14, 15, and 16) proteins ([Fig. 1](#fig1){ref-type="fig"}b). The sera from the two healthy control dogs did not react with any FCS proteins. These results suggest that the 66-kDa band obtained in the immunoblot analysis should contain the most common IgE-reactive component(s) of FCS in the dogs.Fig. 1(a) SDS-PAGE analysis of FCS. An FCS sample (2 μg/lane) was subjected to SDS-PAGE through a 5--20% gradient polyacrylamide gel under reducing conditions, and the gel was then stained with Coomassie brilliant blue. Molecular weight size markers are indicated along the left side. (b) Immunoblot analysis of serum samples from dogs that developed post-vaccination allergic reactions to detect IgE directed to FCS components. Numbers 1--16 indicate the numbers of the dogs that exhibited allergic reactions after vaccination. N1 and N2 indicate the negative control dogs. Molecular weight size markers are indicated along the left side.

Based on the results of SDS-PAGE for FCS ([Fig. 1](#fig1){ref-type="fig"}a), the 66-kDa band that reacted with IgE in the immunoblot analysis ([Fig. 1](#fig1){ref-type="fig"}b) was suspected to be BSA, which is an FCS component. Therefore, we then examined IgE reactivity to purified BSA by using sera from the 14 dogs that were found to react with the 66-kDa band in the immunoblot analysis for FCS. Serum IgE directed to purified BSA was detected in four (Nos. 1--4) of the 14 dogs, but was neither detected in the remaining 10 dogs that showed post-vaccination allergic reactions nor in the two healthy control dogs ([Fig. 2](#fig2){ref-type="fig"}b). This finding indicated that the 66-kDa protein of FCS contained not only BSA but also other proteins that could be allergenic to the dogs. In addition, based on this result, it can be speculated that if we conducted an immunoblot inhibition assay for investigating the relationship between the 66-kDa protein of FCS and BSA in the four dogs, serum IgE directed to the 66-kDa protein of FCS would not be completely inhibited by BSA.Fig. 2(a) SDS-PAGE analysis of BSA. A BSA sample (1 μg/lane) was subjected to SDS-PAGE through a 5--20% gradient polyacrylamide gel under reducing conditions, and the gel was then stained with Coomassie brilliant blue. Molecular weight size markers are indicated along the left side. (b) Immunoblot analysis of serum samples from dogs that developed post-vaccination allergic reactions to detect IgE directed to purified BSA. Numbers indicate the numbers of the 14 dogs in which IgE directed to the approximately 66-kDa protein detected in the immunoblot analysis of FCS was present. N1 and N2 indicate the negative control dogs. Molecular weight size markers are indicated along the left side.

Protein bands corresponding to molecular weights of approximately 25-, 50-, 66-, 75-, 120-, and 175-kDa were detected in the immunoblot analysis, which were performed to examine the IgE-binding FCS components; of these, the 25-, 50-, and 75-kDa bands were suspected to correspond to bovine IgG light chains, heavy chains, and transferrin, respectively, based on the molecular weights. In addition, it was reported that IgE directed to bovine fibronectin was shown in the sera form dogs after injection with a rabies vaccine ([@bib4]). Therefore, we further investigated serum IgE reactivity to the purified FCS components including bovine IgG, transferrin, and fibronectin by the immunoblot analysis. However, we did not detect any positive bands in these immunoblot analyses (data not shown). Since, IgE-reactive epitopes of these bovine proteins might have been destroyed by the denaturing step in the SDS-PAGE, further analysis using native antigen without denaturation is necessary to identify possible IgE-reactive FCS components that may be associated with allergic reactions after vaccination in dogs.

In the present study, in four of the 16 dogs, IgE directed to BSA was present in the sera. It was found that large amounts of BSA were included in all of the vaccines for dogs currently marketed in Japan ([@bib8]). Moreover, most of these vaccines are produced and marketed in the U.S. and Europe. It is highly plausible that the BSA in live vaccines is derived from FCS, which is routinely used in cell culture for growing virus strains that are included in vaccines for dogs, and the BSA in inactivated vaccines is derived from the culture media for leptospira. Therefore, it is conceivable that not only the FCS in live vaccines but also the BSA in inactivated leptospira vaccines can function as allergens that induce allergic reactions after vaccination in dogs.

Both serum IgE directed to the injected vaccines and FCS were detected not only in the sera of the seven dogs that showed allergic reactions within 60 min after vaccination but also in those of nine dogs that exhibited allergic reactions from 2--20 h after vaccination; the dogs of the latter group were clinically classified as nonimmediate-type allergic reactions. In humans, it was shown that children who developed allergic reactions several hours after vaccination did not have serum IgE directed to the injected vaccines ([@bib5]). In these children, T-lymphocyte-mediated immune reactions were found to be involved in the development of nonimmeditate-type allergic reactions after vaccination ([@bib5]). One of the possible explanations for the result obtained in this study is that the dog owners or the veterinarians might have missed the initial clinical signs of allergic reactions soon after vaccination, although some private veterinarians did report the onset of allergic reactions 2--20 h after vaccination. Alternatively, IgE might have also been involved in the development of nonimmediate-type allergic reactions after vaccination in the dogs. It was recently reported that IgE also contributed to the development of delayed-onset allergic inflammation in mice through the basophil-mediated immune response ([@bib6]). To clarify the immunological mechanisms underlying the development of nonimmediate-type allergic reactions after vaccination in dogs, further studies are needed.

In humans, allergen-free vaccines have successfully reduced the incidence of allergic reactions after vaccination ([@bib10]). The present study clearly indicates that a variety of FCS components including BSA, but not a single component, can function as allergens in dogs that developed allergic reactions after vaccination. Therefore, together with our previous study, which showed that stabilizer proteins such as gelatin and casein also functioned as allergens in vaccines for dogs ([@bib8]), it can be concluded that FCS, BSA, and stabilizer proteins should be eliminated from the live and inactivated components of vaccines for dogs in order to manufacture safe vaccines with very low incidence of post-vaccination allergic reactions.
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[^1]: Criteria for the grouping of vaccines are described in the materials and methods. F: female, M: male.
